OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO

OPRX 12.23.2024

Full Press ReleaseSEC FilingsOur OPRX Tweets

About Gravity Analytica

Recent News

  • 12.23.2024 - OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO
  • 11.21.2024 - Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

Recent Filings

  • 01.10.2025 - 8-K Current report
  • 01.08.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
  • 12.27.2024 - 4 Statement of changes in beneficial ownership of securities
PDF Version

WALTHAM, Mass.,Dec. 23, 2024(GLOBE NEWSWIRE) --OptimizeRx Corp.(the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced thatWilliam J. Febbo, Chief Executive Officer (CEO) and Board Member, will be departing the Company, effective as ofDecember 31, 2024, to pursue other opportunities.Mr. Febbowill provide the Company with advisory services throughMarch 31, 2025. The Company’s Board of Directors has retained a search firm to assist in this transition.

“The time is right to pass the reins on to an incredible team, ready to carry the legacy forward with strength and purpose,” underscoredMr. Febbo. “With a clear market opportunity and the ability to deliver, they have my ongoing and unwavering support.”

“We are extremely grateful for Will’s leadership at the helm ofOptimizeRxfor nearly nine years,” saidLynn Vos, Chairperson of OptimizeRx’s Board of Directors. “During his tenure, Will grew the Company exponentially, partnering with the top pharmaceutical companies, and he transformed the Company’s capabilities from a single point of care product to an unrivaled omnichannel platform. We believe the foundation he’s helped build will positionOptimizeRxfor meaningful growth over the coming years.”

“The Board of Directors is very pleased to announce thatStephen Silvestrohas been appointed as the interim CEO while a search of candidates is conducted,” continuedLynn Vos. “Steve started atOptimizeRxover six years ago and has led our commercial organization during that time as the Chief Commercial Officer prior to becoming the Company’s President last year, and he will continue to be supported by our extremely experienced and talented extended leadership team.”

“I am honored to have the Board’s trust and will remain resolute on scaling our business as we differentiate ourselves within the market through our technology and continue to build meaningful strategic partnerships with our clients. We will be laser-focused on operational excellence while ensuring we delight our clients and forge stronger relationships with valued business partners,” addedSteve Silvestro.

The Company reaffirms its financial guidance for the full year 2024 and expects it will come in at the higher end of its guidance range for revenue and adjusted EBITDA.

AboutOptimizeRx

OptimizeRxprovides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 2 millionU.S.healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary digital point-of-care network, as well as mass digital communication channels,OptimizeRxhelps life sciences organizations engage and support their customers.

For more information, follow the Company onTwitter,LinkedInor visitwww.optimizerx.com.

Important Cautions Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans, future performance. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, seasonal trends, our ability to maintain our contracts with electronic prescription platforms, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year endedDecember 31, 2023, its subsequent Quarterly Reports on Form 10-Q, and its other filings with theSecurities and Exchange Commission.

OptimizeRx ContactAndy D’Silva, SVP Corporate Financeadsilva@optimizerx.com

Investor Relations ContactSandya von der WeidLifeSci Advisors, LLCsvonderweid@lifesciadvisors.com

Primary Logo

Source: OptimizeRx Corporation

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com